2187 ⎘
Genetically modified animals; Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
METHODS FOR IDENTIFYING MBLAC1-DEPENDENT MOLECULAR NETWORKS
#302Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof
#303ENGINEERING OF HUMANIZED CAR T-CELL AND PLATELETS BY GENETIC COMPLEMENTATION
#304THERAPIES BASED ON CONTROL OF REGULATORY T CELL STABILITY AND FUNCTION VIA A NEUROPILIN-1:SEMAPHORIN AXIS
#305Fumarylacetoacetate hydrolase (FAH)-deficient and immunodeficient rats and uses thereof
#306EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA)
#307Methods of Genetic Modification of a Cell
#308Methods of engineering human induced pluripotent stem cells to produce liver tissue
#309Genetically modified non-human animal with human or chimeric SIRPa
#310Genetically modified non-human animal with human or chimeric OX40
#311Genetically modified non-human animal with human or chimeric CTLA-4
#312Method of using a genetically modified mouse that expresses a humanized CTLA-4 gene
#313HLA Class II Deficient Cells, HLA Class I Deficient Cells Capable of Expressing HLA Class II Proteins, and Uses Thereof
#314Genetically modified non-human animal with human or chimeric GITR
#315Preventive or therapeutic agent for kidney disease
#316Production method for conditional knockout animal
#317Method of constructing zebrafish mutants
#318Genetically modified non-human animal with human or chimeric OX40
#319Genetically modified mouse comprising a chimeric TIGIT
#320Parkinson's disease model and methods
#321ANIMAL MODEL FOR DRUG DEVELOPMENT
#322Application of GPR45 gene
#323RODENT MODELS WITH AUTISTIC FEATURES
#324Genetically modified non-human animal with human or chimeric CD28
#325GENETICALLY MODIFIED CELLS, TISSUES, AND ORGANS FOR TREATING DISEASE
#326Method of inactivating a FEL D1 gene using crispr
#327Genetically modified non-human animal with human or chimeric TIGIT
#328Non-human animals having a humanized lymphocyte-activation gene 3
#329Immunodeficient non-human animal
#330TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
#331Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV)
#332MRAP2 KNOCKOUTS
#333Endoplasmic reticulum-targeting nanovehicles and methods for use thereof
#334Genetically modified mice and engraftment
#335Repressors of viral infection
#336GENE FOR IDENTIFYING INDIVIDUALS WITH FAMILIAL DYSAUTONOMIA
#337Cancer Treatment and Immune System Regulation Through FAT10 Pathway Inhibition
#338Transferrin receptor transgenic models
#339GPCR (GPR113) INVOLVED IN FAT, FATTY ACID AND/OR LIPID-ASSOCIATED TASTE AND USE IN ASSAYS FOR IDENTIFYING TASTE MODULATORY
#340Genetically modified non-human animals and methods for producing heavy chain-only antibodies
#341NON-HUMAN ANIMAL EXHIBITING DIMINISHED UPPER AND LOWER MOTOR NEURON FUNCTION AND SENSORY PERCEPTION
#342AAV delivery of shRNA for treatment of pancreatic cancer
#343Engineering of Humanized Kidney by Genetic Complementation
#344Genetically modified major histocompatibility complex mice
#345Genetically modified major histocompatibility complex mice
#346Construction Method for Immunodeficient Rat Model
#347Animal model of brain tumor and manufacturing method of animal model
#348Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
#349REGULATORS OF B CELL-MEDIATED IMMUNOSUPPRESSION
#350METHOD FOR ESTABLISHING A NON-HUMAN MAMMALIAN ANIMAL MODEL SUFFERING FROM OBESITY OR RELATED DISEASE AND USE THEREOF
#351Genetically Edited Animal
#352Non-human animals having a disruption in a C9ORF72 locus
#353Humanized non-human animals with restricted immunoglobulin heavy chain loci
#354Use of C1q/TNF-related protein-1 (CTRP1) to treat fatty liver disease
#355METHODS AND COMPOSITIONS RELATING TO IMPROVED HUMAN RED BLOOD CELL SURVIVAL IN GENETICALLY MODIFIED IMMUNODEFICIENT NON-HUMAN ANIMALS
#356ANIMAL MODELS FOR POLYCYSTIC KIDNEY DISEASE
#357Animal models and therapeutic molecules
#358COMPOSITIONS AND METHODS FOR INHIBITING ENDOGENOUS IMMUNOGLOBULIN GENES AND PRODUCING TRANSGENIC HUMAN IDIOTYPE ANTIBODIES
#359Human liver chimeric mouse with deficient P450 oxidoreductase
#360Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith
#361Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
#362VE-PTP KNOCKOUT
#363Compositions and methods for modulating neuronal excitability and motor behavior
#364Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
#365GENERATION OF GENETICALLY ENGINEERED ANIMALS BY CRISPR/CAS9 GENOME EDITING IN SPERMATOGONIAL STEM CELLS
#366Co-activation of mTOR and STAT3 pathways to promote neuronal survival and regeneration
#367Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
#368Methods of treating mitochondrial disorders
#369EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA)
#370PHARMACOKINETIC ANIMAL MODEL
#371Methods and compositions for the targeted modification of a mouse ES cell genome
#372ACTIVATION OF TRPV4 ION CHANNEL BY PHYSICAL STIMULI AND CRITICAL ROLE FOR TRPV4 IN ORGAN-SPECIFIC INFLAMMATION AND ITCH
#373Tissue products derived from animals lacking any expression of functional alpha 1, 3 galactosyltransferase
#374Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
#375METHOD OF PRODUCING INFERTILE FISH AND EGG-PRODUCING AQUATIC ANIMALS AND OF DELIVERING COMPOUNDS INTO EGGS AND EMBRYOS
#376In vivo gene silencing by chemically modified and stable siRNA
#377Pathogen-resistant animals having modified CD163 genes
#378NON-HUMAN ANIMALS HAVING A MUTANT KYNURENINASE GENE
#379Methods for the treatment of Danon disease and other disorders of autophagy
#380METHOD FOR IDENTIFYING BIOACTIVE PROTEIN, AND BIOACTIVE PROTEIN OBTAINED BY SAID METHOD
#381Compositions and methods for genetically modifying myosin phosphatase target subunit (Mypt1) gene for lowering blood pressure
#382Methods and compositions for modifying a mutant dystrophin gene in a cell's genome
#383LDL receptor gene knockout, genetically-engineered hamster
#384METHOD FOR PREPARING A GENE KNOCK-OUT CANINE WITH SOMATIC CELL CLONING TECHNOLOGY
#385TRANSGENIC MICE
#386Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
#387Inhibitors of α-tubulin acetylation for the treatment of pain
#388Transgenic pig which simultaneously expresses HO-1 gene and TNFR1-Fc gene, and comprises knocked-out GGTA1 gene, and use thereof
#389MYO1A for predicting conversion of acute pain into chronic pain and use of MYO1A for therapy of pain
#390Use of guaiacol for the prevention and treatment of glycogen storage disease
#391Genetically modified chicken egg with an exogenous sequence knocked into the ovalbumin gene
#392Treatment of heart disease by inhibtion of the action of muscle A-kinase anchoring protein (mAKAP)
#393Methods of modifying genes in eukaryotic cells
#394Porcine reproductive and respiratory syndrome virus resistant animals
#395Transgenic mice
#396ORGAN HUMANIZED MOUSE
#397INHIBITING GENE EXPRESSION WITH dsRNA
#398Mutations in rhodopsin gene in zebrafish and uses thereof
#399Methods of treating muscular dystrophy
#400NAD BIOSYNTHESIS AND PRECURSORS FOR THE TREATMENT AND PREVENTION OF CANCER AND PROLIFERATION
#401Porcine animals lacking expression of functional alpha 1, 3 galactosyltransferase
#402Methods of treating or preventing pruritis by blocking natriuretic polypeptide b
#403Application of PCSK9 inhibitors in the preparation of drugs for the treatment of inflammatory immune diseases
#404Inducible modification of a cell genome
#405Method of producing infertile fish and egg-producing aquatic animals and of delivering compounds into eggs and embryos
#406Method for measuring tumor burden in patient derived xenograft (PDX) mice
#407Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis
#408METHOD FOR PREPARING A CANINE MODEL OF ATHEROSCLEROSIS
#409Methods and compositions for treatment of atherosclerosis
#410Generation and correction of a humanized mouse model with a deletion of dystrophin exon 44
#411Motor neuron-specific expression vectors
#412Method for treating a degenerative neurological disorders comprising administering ASM inhibitor
#413Method of making trabecular bone
#414Non-human animal models of retinoschisis
#415Methods and compositions for targeted genetic modifications and methods of use
#416Androgenetic haploid embryonic stem cell (AG-HAESC), and preparation method and use thereof
#417Composite comprising antibody capable of binding to intranuclear protein of influenza virus
#418Immunity enhancing agent for cancer by Allergin-1 antagonist
#419Compositions and methods for treating bone diseases
#420Protein having nuclease activity, fusion proteins and uses thereof
#421Transferrin receptor transgenic models
#422MULTIPLEX GENE EDITING
#423ANTIBODY THAT BINDS MURINE WISE PROTEIN
#424Methods and pharmaceutical compositions for improving wound healing using CD24
#425Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
#426PCSK9 INHIBITORY POLYPOLYPEPTIDES AND METHODS OF USE
#427INHIBITING CTRP5 ACTION TO IMPROVE INSULIN RESISTANCE ASSOCIATED WITH OBESITY AND TYPE 2 DIABETES
#428Methods and agents for treating Alzheimer's disease
#429Non-HLA matched humanized NSG mouse model with patient-derived xenograft
#430TRANSGENIC PIGS WITH GENETIC MODIFICATIONS OF SLA
#431Humanized skeletal muscle
#432Micro-RNA family that modulates extracellular matrix genes and uses thereof
#433AUF1 ENCODING COMPOSITIONS FOR MUSCLE CELL UPTAKE, SATELLITE CELL POPULATIONS, AND SATELLITE CELL MEDIATED MUSCLE GENERATION
#434Double knockout (GT/CMAH-KO) pigs, organs and tissues
#435ANTIBODY PRODUCING NON-HUMAN ANIMALS
#436ANTIBODY PRODUCING NON-HUMAN ANIMALS
#437Antibody producing non-human animals
#438ANTIBODY PRODUCING NON-HUMAN ANIMALS
#439Antibody producing non-human animals
#440Antibody producing non-human animals
#441Non-human animals having an engineered immunoglobulin Λ light chain locus
#442IL-17A binding proteins
#443Fabry disease gene therapy
#444ANIMAL MODELS FOR CARDIOMYOPATHY
#445Genetic modification of pigs for xenotransplantation
#446Transgenic chicken comprising an inactivated immunoglobulin gene
#447Method of treating vitiligo using mutant HSP70i
#448Gene editing of reproductive hormones to sterilize aquatic animals
#449Prevention and/or treatment of hearing loss or impairment
#450IMMUNOTHERAPY COMPOSITIONS AND METHODS FOR TREATMENT OF TAUOPATHY AND TRANSGENIC MOUSE
#451Genetically modified non-human animals and methods of use thereof
#452Generation of an inducible pericyte-specific CRE mouse model
#453Genetically modified pig cells with an inactivated Etv2 gene
#454Identification of a 5-Gene Expression Signature Predicting Clinical Outcome of Patients with Brain Tumors
#455Porcine reproductive and respiratory syndrome virus resistant animals
#456ACTIVATION OF TRPV4 ION CHANNEL BY PHYSICAL STIMULI AND CRITICAL ROLE FOR TRPV4 IN ORGAN-SPECIFIC INFLAMMATION AND ITCH
#457Gene knockout method
#458Humanized FcγR mice
#459WISE/SOST NUCLEIC ACID SEQUENCES AND AMINO ACID SEQUENCES
#460Co-activation of mTOR and STAT3 pathways to promote neuronal survival and regeneration
#461Non-human animals expressing pH-sensitive immunoglobulin sequences
#462Composite comprising antibody capable of binding to intranuclear protein of influenza virus
#463P21-activated kinase inhibitor domain targeted transgenic mouse
#464RNA interference mediating small RNA molecules
#465Antibodies, variable domains and chains tailored for human use
#466TRIPLE TRANSGENIC PIGS SUITABLE FOR XENOGRAFT
#467Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions
#468SIGNATURES AND PCDETERMINANTS ASSOCIATED WITH PROSTATE CANCER AND METHODS OF USE THEREOF
#469Parkinsons disease model and methods
#470Cancer treatment and immune system regulation through FAT10 pathway inhibition
#471COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEUROLOGICAL DISEASE
#472TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
#473Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
#474NON-HUMAN ANIMALS HAVING A MUTANT KYNURENINASE GENE
#475Method for producing polyclonal antibodies with improved complement-dependent cytotoxicity
#476Telomerase reverse transcriptase-based therapies
#477Knockout mouse, method for screening substance for suppressing mesial temporal lobe epilepsy, and method for selecting technique for suppressing mesial temporal lobe epilepsy
#478Production of fertile XY female mice from XY mouse ES cells
#479MrgprX2/MrgprB2 expressing cell based assay to detect pseudo-allergic drug reactions and to identify blockers to prevent the adverse reactions
#480MODELS OF THROMBOTIC THROMBOCYTOPENIC PURPURA AND METHODS OF USE THEREOF
#481PERFORIN 2 DEFENSE AGAINST INVASIVE AND MULTIDRUG RESISTANT PATHOGENS
#482Ungulates with Genetically Modified Immune Systems
#483Method of preventing polycystic kidney disease and PKD animal model with exogenous neutrophil gelatinase-associated lipocalin
#484GENOME EDITING USING CAS9 NICKASES
#485Genetically modified mice and engraftment
#486Preventive or therapeutic agent for kidney disease
#487NON-HUMAN ANIMALS EXPRESSING HUMANIZED CD3 COMPLEX
#488Methods of treating fragile X syndrome and related disorders
#489ENGINEERING OF HUMANIZED CAR T-CELL AND PLATELETS BY GENETIC COMPLEMENTATION
#490METHODS FOR TREATMENT AND PREVENTION OF TAUOPATHIES AND AMYLOID BETA AMYLOIDOSIS BY MODULATING CRF RECEPTOR SIGNALING
#491APPLICATION OF GPR45 GENE
#492Non-human animals having a humanized lymphocyte-activation gene 3
#493NANOS KNOCK-OUT THAT ABLATES GERMLINE CELLS
#494Genetically modified major histocompatibility complex mice
#495Animal models and therapeutic molecules
#496Genetically modified non-human mammals and cells
#497Method of genetically altering and producing allergy free cats
#498ANIMAL MODELS AND THERAPEUTIC MOLECULES - Track 1
#499Transgenic mice having a human major histocompatibility complex (MHC) phenotype, experimental uses and applications
#500DNA methyltransferases for the treatment and prevention of arthritis
#501Method for screening gene expression in lincRNA-deficient mice or rats
#502Methods and compositions for the targeted modification of a mouse embryonic stem cell genome
#503Methods and compositions for mitochondrial replacement therapy
#504Mouse model of hyperuricemia
#505Progranulin (PGRN) and its derivatives for diagnosis and treatment of lysosomal storage diseases
#506Mouse λ light chain locus
#507Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibitors
#508Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
#509Pathogen-resistant animals having modified CD163 genes
#510Methods of treating or preventing pruritis by blocking natriuretic polypeptide B
#511Methods for treating diet-induced obesity by decreasing or inhibiting P2Y2 purinergic receptor expression or activity
#512Methods for treating disorders that involve immunoglobulin A
#513Genetically modified non-human animals and methods of use thereof
#514Interleukin 2 receptor gamma gene targeting vector, production of immune cell-deficient transgenic cloned mini pig having vector introduced therein, preparation method therefor and use thereof
#515Recombination activating gene 2 gene targeting vector, production of SCID-like miniature pigs by TALEN-mediated gene targeting and use thereof
#516COMPOSITIONS AND METHODS FOR PRODUCING GENETICALLY MODIFIED ANIMALS
#517Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
#518Animal models and therapeutic molecules
#519ANIMAL MODELS AND THERAPEUTIC MOLECULES
#520Non-human animals having a disruption in a C9ORF72 locus
#521Compositions and methods for treating autoimmune and inflammatory diseases
#522Anti-tumor properties of Dickkopf 3b
#523Transgenic transchromosomal rodents for making human antibodies
#524Gene editing in the oocyte by Cas9 nucleases
#525Histidine engineered light chain antibodies and genetically modified non-human animals for generating same
#526Humanized monoclonal antibodies from a transgenic rat
#527TRANSGENIC BIRDS THAT PRODUCE CHIMERIC HUMAN IMMUNOGLOBULINS
#528Promoter-regulated differentiation-dependent self-deleting cassette
#529Transgenic chicken comprising an inactivated immunoglobulin gene
#530Generation of heavy-chain only antibodies in transgenic animals
#531Antibodies that specifcally bind Sost and Wise peptides
#532Method of producing infertile fish and egg-producing aquatic animals and of delivering compounds into eggs and embryos
#533Multi-transgenic pigs for diabetes treatment
#534Immunocompromised ungulates
#535METHODS AND MATERIALS FOR PRODUCING TRANSGENIC ARTIODACTYLS
#536Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception
#537Animal models and therapeutic molecules
#538Fumarylacetoacetate hydrolase (Fah)-deficient and immunodeficient rats and uses thereof
#539Compositions and methods for modulating neuronal excitability and motor behavior
#540Mitochondrial targeting and therapeutic use thereof
#541Mouse model for engraftment potential
#542Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
#543Activation of TRPV4 ion channel by physical stimuli and critical role for TRPV4 in organ-specific inflammation and itch
#544Compositions and methods for increasing bone mineralization
#545Methods and compositions for targeted genetic modification through single-step multiple targeting
#546GENETICALLY MODIFIED RAT MODELS FOR DRUG METABOLISM
#547GENETICALLY MODIFIED RAT MODELS FOR PAIN
#548Animal models and therapeutic molecules
#549miRNA-regulated differentiation-dependent self-deleting cassette
#550Micro-RNA family that modulates fibrosis and uses thereof
#551Micro-RNA family that modulates fibrosis and uses thereof
#552Micro-RNA family that modulates fibrosis and uses thereof
#553MRAP2 KNOCKOUTS
#554Animal Models of Ataxia-Telangiectasia (A-T)
#555COMPOSITIONS AND METHODS FOR THE STUDY AND TREATMENT OF ACUTE KIDNEY INJURY
#556Prophylactic and/or therapeutic agent for inflammatory disease, and method for screening prophylactic and/or therapeutic drug for inflammatory disease
#557Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof
#558Methods and agents for treating Alzheimer's disease
#559RNA sequence-specific mediators of RNA interference
#560MULTIPLEX GENE EDITING
#561TGIF2-induced reprogramming of hepatic cells to pancreatic progenitor cells and medical uses thereof
#562Activation of innate immunity by miRNA for cancer and infection treatment
#563Gene editing in the oocyte by CAS9 nucleases
#564Methods for producing a mouse XY embryonic (ES) cell line capable of producing a fertile XY female mouse in an F0 generation
#565Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
#566Reduction of TGF beta signaling in myeloid cells in the treatment of cancer
#567Weight loss by inhibition of gastrokine
#568Genetically modified non-human animals expressing human EPO
#569Method and apparatus for data transmission using multiple transmit antennas
#570Cancer treatment and immune system regulation through FAT10 pathway inhibition
#571Fibrotic non-human animal, and use thereof
#572NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation
#573Low affinity FCGR deficient mice
#574Genetically edited pigs comprising a modification in the RELA gene
#575In vivo gene silencing by chemically modified and stable siRNA
#576Medicament comprising activity modulator for CD300a-expressing cell associated with allergic disease, CD300a gene-deficient mouse, and use of activity modulator for CD300a-expressing cell
#577Therapies based on control of regulatory T cell stability and function via a neuropilin-1:semaphorin axis
#578Double knockout (GT/CMAH-KO) pigs, organs and tissues
#579Composition and methods for the prevention and treatment of diet-induced obesity
#580Activation of TRPV4 ion channel by physical stimuli and critical role for TRPV4 in organ-specific inflammation and itch
#581Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
#582Antibodies that specifically bind to DRG11-responsive (DRAGON) proteins
#583Methods for producing a population of pancreatic beta-cells
#584Antibodies that specifically bind to DRG11-responsive (DRAGON) proteins
#585Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
#586Complex chromosome engineering for production of human antibodies in transgenic animals
#587Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP)
#588Mice that make heavy chain antibodies
#589Methods of treating metabolic disease
#590Tissue products derived from animals lacking any expression of functional alpha 1, 3 galactosyltransferase
#591Fumarylacetoacetate hydrolase (Fah)-deficient pigs and uses thereof
#592Anti-tumor properties of Dickkopf 3b
#593Methods and compositions for the targeted modification of a mouse genome
#594Use of antagonists targeting metallothionein to treat intestinal inflammation
#595Antibody that binds murine wise protein
#596RNA interference mediating small RNA molecules
#597Transgenic non-human vertebrate for the in vivo production of dual specificity immunoglobulins or hypermutated heavy chain only immunoglobulins
#598Miniature swine transgenic for one or more coagulation factors
#599GENETICALLY MODIFIED RAT MODELS FOR PAIN
#600GENETICALLY MODIFIED RAT MODELS FOR PHARMACOKINETICS